Atherosclerosis Drugs Global Market Report 2024

The atherosclerosis drugs market size has grown steadily in recent years. It will grow from $48.72 billion in 2023 to $50.5 billion in 2024 at a compound annual growth rate (CAGR) of 3.6%. The expansion observed in the historical period can be credited to efforts in cholesterol management, the control of blood pressure, the implementation of smoking cessation programs, research and development initiatives, and advancements in diagnostic technologies.

The atherosclerosis drugs market size is expected to see steady growth in the next few years. It will grow to $57.03 billion in 2028 at a compound annual growth rate (CAGR) of 3.1%. The anticipated growth in the forecast period can be ascribed to the emergence of new therapies, advancements in precision medicine, the focus on immunotherapy and inflammation, innovations in lipid management, and regulatory support. Key trends projected for the forecast period encompass the utilization of biologic therapies, the implementation of gene editing and gene therapy, the adoption of combination therapies, personalized treatment approaches, and the integration of telemedicine and remote monitoring.

The growth of the atherosclerosis drug market is expected to be propelled by the increasing prevalence of cardiovascular diseases. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, with atherosclerosis specifically involving the accumulation of fats, cholesterol, and other substances on artery walls. This condition, marked by plaque buildup inside the arteries, contributes to cardiovascular diseases such as coronary heart disease and stroke. Atherosclerosis drugs play a crucial role in treating cardiovascular diseases by reducing the risk of complications and managing underlying factors such as elevated cholesterol levels and the formation of blood clots. For example, a report published by The Office for National Statistics in March 2022 indicated that between 2020 and 2021, 19,440 to 20,061 people in the UK died due to heart attacks. Additionally, according to the Centers for Disease Control and Prevention in May 2023, 1 in 20 adults aged 20 and older in the US had cardiovascular diseases, with 695,000 people suffering from these conditions in 2021, and 375,476 deaths attributed to cardiovascular diseases that same year. Thus, the prevalence of cardiovascular diseases is expected to drive the atherosclerosis drug market.

The growth of the atherosclerosis drug market is anticipated to be fueled by the increasing aging population. The aging population refers to a demographic shift characterized by a significant rise in the proportion or number of individuals within a society who are considered elderly or senior citizens. Atherosclerosis drugs play a critical role in addressing elevated cardiovascular risks in the aging population, contributing to prevention, management, and treatment for overall well-being. For instance, as of June 2023, The United States Census Bureau reported a 0.2-year increase in the country's median age to 38.9 years in 2022, indicating a continued aging trend in the population. Consequently, the growing aging population is a driving force behind the growth of the atherosclerosis drug market.


Product innovation emerges as a prominent trend gaining momentum in the atherosclerosis drugs market. Major companies within the market are actively engaged in the development of innovative drugs and securing approvals as part of their strategy to maintain a strong market position. For example, in December 2021, Novartis AG, a pharmaceutical company based in Switzerland, obtained approval from the US Food and Drug Administration (FDA) for Leqvio (inclisiran), a groundbreaking siRNA designed to lower cholesterol and treat individuals with atherosclerotic cardiovascular disease. Administered through subcutaneous injection, this novel drug effectively reduces low-density lipoproteins (LDL) cholesterol levels in the bloodstream for adults with clinical atherosclerotic cardiovascular disease, offering a new treatment option for those unable to achieve their LDL cholesterol goals with existing therapies.

Major companies operating in the atherosclerosis drugs market are diversifying their product portfolios by introducing anti-inflammatory drugs to enhance market profitability. Anti-inflammatory drugs for atherosclerosis are specifically formulated to alleviate inflammation associated with the condition characterized by plaque buildup in arteries. For instance, AGEPHA Pharma, a European manufacturer of medical products, launched LODOCO. This drug, comprising colchicine in 0.5 mg tablets, received approval from the U.S. FDA as an innovative anti-inflammatory atheroprotective cardiovascular treatment. LODOCO has demonstrated efficacy in reducing the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with atherosclerotic disease or multiple cardiovascular risk factors. Addressing residual inflammation, a critical factor in atherosclerotic cardiovascular disease (ASCVD), LODOCO can be used alone or in combination with cholesterol-lowering medications, marking a significant breakthrough in cardiovascular care.

In April 2023, Chiesi Farmaceutici S.p.A., an Italian pharmaceutical company, completed the acquisition of Amryt Pharma plc for an approximate sum of $1.25 billion. This strategic move aims to expand Chiesi Farmaceutici S.p.A.'s rare disease portfolio, gain access to Amryt's pipeline of developmental candidates, and establish a presence in the US market. Amryt Pharma plc, based in Ireland, specializes in the development of atherosclerosis drugs for the treatment of rare diseases, including atherosclerosis and generalized lipodystrophies.

Major companies operating in the atherosclerosis drugs market report are Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co.Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc., Anthera Pharmaceuticals Inc.

North America was the largest region in the atherosclerosis drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the atherosclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary categories of atherosclerosis drugs encompass anti-platelet medications, fibric acid and omega-3 fatty acid derivatives, angiotensin-covering enzyme (ACE) inhibitors, diuretics, cholesterol-lowering medications, beta-blockers, calcium channel blockers, and other related medications. Antiplatelet medications are drugs that hinder the formation of blood clots by impeding the aggregation of platelets, which are small cell fragments in the blood. These drugs can be administered orally or through injections and are primarily dispensed through various channels, including hospital pharmacies, online pharmacies, retail pharmacies, and others.

The atherosclerosis drugs market research report is one of a series of new reports that provides atherosclerosis drugs market statistics, including atherosclerosis drugs industry global market size, regional shares, competitors with an atherosclerosis drugs market share, detailed atherosclerosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the atherosclerosis drugs industry. This atherosclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The atherosclerosis drugs market consists of sales of statins, rosuvastatin, atorvastatin, fibrates, bile acid sequestrants, nitrates, ezetimibe, and blood pressure medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.